Published in Biotech Business Week, July 3rd, 2006
The opening of these sites is expected to dramatically increase the number of patients being treated with BiovaxID during the next 12 to 18 months. The filings have been submitted by the contract research organizations, which will manage the trials for Biovest in Ukraine and Russia and will be responsible for monitoring patient recruitment and overseeing...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.